A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Trial ID or NCT#
Status
Purpose
This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.
Official Title
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Eligibility Criteria
Contact us to find out if this trial is right for you.
Contact
ccto-office@stanford.edu
650-498-7061
View on ClinicalTrials.gov